cchfv hoti strain  (Azenta)

Journal: PLOS Neglected Tropical Diseases

Article Title: Crimean-Congo hemorrhagic fever virus NSm protein inhibits the type I interferon signaling by binding to STAT2

doi: 10.1371/journal.pntd.0013695

Figure Lengend Snippet: Sequence alignment of the NSm was conducted based on the amino acid sequences of representative CCHFV strain. DEG_Nend_UBRbox_1 and SPOP motif are indicated by a box. The genotype of each strain is shown in parentheses.

Article Snippet: The open reading frame (ORF) sequence of the GP of the CCHFV Hoti strain was synthesized (Genewiz).

Techniques: Sequencing

Journal: NPJ Vaccines

Article Title: Replicating RNA vaccine confers durable immunity against Crimean Congo hemorrhagic fever virus challenge in mice

doi: 10.1038/s41541-024-01045-1

Figure Lengend Snippet: WT C57BL6/J mice were vaccinated prime boost with 1 µg repNP + repGc RNA 4 weeks apart. Immunogenicity of vaccination was measured 1-, 3-, 6-, 9-, and 12-months post-boost vaccination. At each time point, groups of six mice were evaluated for CCHFV specific immune responses via a whole virion IgG ELISA shown with endpoint titers and b recombinant antigen ELISA to the CCHFV nucleocapsid (NP) and glycoprotein c (Gc) proteins. Sham mice are combined from all timepoints. Dashed lines indicate background absorbance of wells. CCHFV-specific T-cell responses were measured via IFNγ ELISpot shown as c cumulative spot-forming cells (SFCs) against peptide pools spanning the entire NP or Gc as well as d cumulative responses to NP and Gc overtime. Statistical comparisons were calculated using a one-way ANOVA with Turkey’s multiple comparison test. ns P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are shown as mean plus standard deviation.

Article Snippet: CCHFV-specific T-cell responses were evaluated as previously described using CCHFV strain Hoti peptides (Genscript) and mouse single-color IFNγ kit (ImmunoSpot) .

Techniques: Immunopeptidomics, Enzyme-linked Immunosorbent Assay, Recombinant, Enzyme-linked Immunospot, Comparison, Standard Deviation

Journal: NPJ Vaccines

Article Title: Replicating RNA vaccine confers durable immunity against Crimean Congo hemorrhagic fever virus challenge in mice

doi: 10.1038/s41541-024-01045-1

Figure Lengend Snippet: Groups of WT C57BL6/J mice vaccinated prime-boost with repNP + repGc were treated with MAR1-5A3 antibody to block the type I IFN response and infected with 100 TCID 50 CCHFV strain UG3010 3-, 6-, 9-, and 12-months post-boost vaccination. At each timepoint, mice were a challenged on “day 0” and groups of mice were assessed for control of viral loads and survival on days 5 and to day 14, respectively, relative to CCHFV challenge. Mice ( N = 8) were monitored for b weight loss and c survival over the course of infection. On day 5 post-infection, mice ( N = 6) were evaluated for control of d viral genome copies via qRT-PCR and e infectious virus via TCID 50 in the blood, liver, and spleen. Dashed lines indicate limit of detection. Statistical comparisons were calculated using a one-way ANOVA with Turkey’s multiple comparison test. ns >0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are shown as mean plus standard deviation.

Article Snippet: CCHFV-specific T-cell responses were evaluated as previously described using CCHFV strain Hoti peptides (Genscript) and mouse single-color IFNγ kit (ImmunoSpot) .

Techniques: Blocking Assay, Infection, Control, Quantitative RT-PCR, Virus, Comparison, Standard Deviation

Journal: NPJ Vaccines

Article Title: Replicating RNA vaccine confers durable immunity against Crimean Congo hemorrhagic fever virus challenge in mice

doi: 10.1038/s41541-024-01045-1

Figure Lengend Snippet: Surviving mice from repNP + repGc 6-, 9-, and 12-months groups were evaluated on day 14 p.i. for CCHFV-specific anamnestic responses. Sera was collected and evaluated for CCHFV-specific antibodies using a recombinant antigen ELISA to the CCHFV NP, Gn, GP38, and Gc. Responses are shown for the 6-, 9-, and 12-month groups as well as comparisons between D0 and D14 for CCHFV-NP and Gc responses. Further, anamnestic CCHFV-specific T-cell responses were measured via b IFNγ ELISpot shown as cumulative SFCs against peptide pools spanning the entire GPC or NP as well as a comparison between D0 and D15 responses to the GPC peptide pool 10. Data from day 0 is duplicated from Fig. and shown here for comparison. Dashed lines indicate limit of detection. Statistical comparisons were calculated using a one-way ANOVA with Turkey’s multiple comparison test. ns >0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are shown as mean plus standard deviation.

Article Snippet: CCHFV-specific T-cell responses were evaluated as previously described using CCHFV strain Hoti peptides (Genscript) and mouse single-color IFNγ kit (ImmunoSpot) .

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Enzyme-linked Immunospot, Comparison, Standard Deviation